Spots Global Cancer Trial Database for androgen deprivation therapy
Every month we try and update this database with for androgen deprivation therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer | NCT05156424 | Exercise Prostate Cancer | Exercise | 18 Years - | Waterford Instituate of Technology | |
| Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | NCT02742675 | Prostate Cancer | Bicalutamide goserelin aceta... flutamide leuprolide acet... triptorelin Definitive Trea... | 18 Years - 80 Years | Fudan University | |
| Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients | NCT02997709 | Prostate Cancer | 30 Years - | University of Miami | ||
| Feasibility and Safety of Physical Exercise in Men With Prostate Cancer | NCT04500080 | Prostate Cancer Androgen Depriv... Radiotherapy | PE Intervention | 18 Years - | Azienda Unità Sanitaria Locale Reggio Emilia | |
| Strategies to Improve Bone Health in Men on ADT | NCT02043236 | Prostate Cancer | Healthy bones p... Bone Health Car... Letter to GP | 50 Years - | University Health Network, Toronto | |
| Feasibility Study for the Assessment of Sleep Quality in Men With Prostate Cancer Starting ADT | NCT02919904 | Prostatic Neopl... Sleep | ARESTM | 18 Years - | Vancouver Prostate Centre | |
| Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624 | NCT05781217 | Prostate Cancer Salvage Radioth... Biochemical Rec... Androgen Depriv... Metastases-free... | triptorelin, go... | 18 Years - | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | |
| Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | NCT02742675 | Prostate Cancer | Bicalutamide goserelin aceta... flutamide leuprolide acet... triptorelin Definitive Trea... | 18 Years - 80 Years | Fudan University | |
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging | NCT06276465 | Prostatic Cance... | Darolutamide 30... Stereotactic bo... Androgen depriv... | 18 Years - | UNICANCER | |
| Exercise and Quality of Life During Androgen Deprivation Therapy | NCT04050397 | Prostate Cancer | Progressive sup... Lecture | 18 Years - | Tampere University Hospital | |
| Physical Function During ARSI Treatment | NCT05612880 | Advanced Prosta... | androgen recept... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy | NCT02050906 | Recurrent Prost... Stage IV Prosta... | behavioral diet... exercise interv... behavioral acti... telephone based... quality-of-life... questionnaire a... | - | Ohio State University Comprehensive Cancer Center | |
| Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON) | NCT04569461 | Prostate Cancer | pembrolizumab Stereotactic bo... Short-term andr... Radical Prostat... | 18 Years - | Duke University | |
| Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer | NCT05917860 | Localized Prost... Castration-Naiv... Intermediate Ri... Prostate Cancer | Degarelix MRI-guided tran... | 40 Years - 80 Years | Turku University Hospital | |
| Exercise for Physical Health in Men With Prostate Cancer | NCT00660686 | Prostatic Neopl... Osteoporosis | Resistance Exer... Flexibility Tra... | 18 Years - 100 Years | OHSU Knight Cancer Institute | |
| Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
| Outcome Of Treatment Of Prostate Cancer at Sohag University Hospital Between 2017 to 2021 | NCT05382182 | Prostate Cancer | androgen depriv... external beam r... | 18 Years - | Sohag University | |
| Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer | NCT00957606 | Prostate Cancer Androgen Depriv... Osteoporosis | blood sampling,... | - | Odense University Hospital | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| Strategies to Improve Bone Health in Men on ADT | NCT02043236 | Prostate Cancer | Healthy bones p... Bone Health Car... Letter to GP | 50 Years - | University Health Network, Toronto | |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| ASCVD Management Using CCTA in Prostate Cancer Patients on ADT | NCT05879913 | Prostate Cancer | Coronary CT Ang... | 40 Years - | Indiana University | |
| Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | NCT03565835 | Prostatic Neopl... | Abiraterone Ace... Prednisone | 18 Years - | Montefiore Medical Center | |
| Contributions to Hypertension With Androgen Deprivation Therapy | NCT05700903 | Androgen Depriv... Prostate Cancer Hypertension Autonomic Dysfu... Renal Disease | Gonadotropin-Re... Androgen recept... Placebo | 40 Years - | University of Colorado, Denver | |
| Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy | NCT01711892 | Prostatic Neopl... Exercise Soccer Training Androgen Depriv... | Soccer training | 18 Years - 75 Years | University of Copenhagen | |
| ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer | NCT05567770 | Prostate Cancer... | Actinium-J591 Stereotactic Bo... Androgen Depriv... | 18 Years - 90 Years | Weill Medical College of Cornell University | |
| Feasibility and Safety of Physical Exercise in Men With Prostate Cancer | NCT04500080 | Prostate Cancer Androgen Depriv... Radiotherapy | PE Intervention | 18 Years - | Azienda Unità Sanitaria Locale Reggio Emilia | |
| The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy | NCT00063609 | Prostate Cancer | zoledronic acid | 18 Years - | Novartis | |
| Walking Football as a Supportive Medicine for Patients With Prostate Cancer | NCT04062162 | Prostate Cancer Androgen Depriv... | Walking footbal... | 18 Years - 85 Years | Associacao de Investigacao de Cuidados de Suporte em Oncologia | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer | NCT02139774 | Prostate Cancer | Walk with Ease | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer | NCT06218667 | Prostate Cancer | Copanlisib Degarelix Radical Prostat... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | NCT01957436 | Metastatic Pros... | abiraterone ace... radiotherapy Androgen Depriv... Docetaxel | 18 Years - | UNICANCER | |
| Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation | NCT01607879 | Prostate Cancer | Standard of car... Standard of car... | 60 Years - | Medical College of Wisconsin | |
| Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer | NCT01214291 | Risk of Bone Fr... | Toremifene | 50 Years - 80 Years | GTx | |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | NCT06274047 | Androgen Axis S... Prostatectomy Prostate Cancer | Apalutamide Androgen Depriv... | 18 Years - | M.D. Anderson Cancer Center | |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | NCT05212857 | Prostate Cancer | Leuprolide acet... Goserelin aceta... Triptorelin ace... Degarelix aceta... Abiraterone ace... Apalutamide Enzalutamide Local treatment... Radiotherapy fo... Radiotherapy fo... | 18 Years - 80 Years | Fudan University | |
| Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy | NCT05746806 | Recurrent Prost... | Ultrahypofracti... Androgen depriv... | 18 Years - 100 Years | Insel Gruppe AG, University Hospital Bern | |
| Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | NCT00776594 | Prostate Cancer | Androgen Depriv... bicalutamide bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | NCT05726292 | Prostate Cancer Prostate Adenoc... | Relacorilant Enzalutamide Placebo (Sugar ... Androgen Depriv... Radical Prostat... | 18 Years - | University of Chicago | |
| Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer | NCT02296229 | Adenocarcinoma ... Stage III Prost... | stereotactic bo... quality-of-life... laboratory biom... androgen depriv... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| PROState Cancer Patients Initiating Hormone Therapy: Effect of Exercise on CARDIOvascular Health (PROSCARDIO) | NCT03776045 | Prostate Cancer | Standard care p... | 50 Years - 80 Years | University of East Anglia | |
| Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists | NCT01366053 | Prostate Cancer | 18 Years - | CMX Research | ||
| Exercise for Physical Health in Men With Prostate Cancer | NCT00660686 | Prostatic Neopl... Osteoporosis | Resistance Exer... Flexibility Tra... | 18 Years - 100 Years | OHSU Knight Cancer Institute | |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | NCT05617885 | Metastatic Pros... Non-metastatic ... Prostate Cancer | Darolutamide Abemaciclib GNRH-A Leuproli... GNRH-A Gosereli... Degarelix | 18 Years - | Dana-Farber Cancer Institute | |
| Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | NCT03543189 | Prostate Cancer Prostate Diseas... | Nivolumab Brachytherapy External Beam R... Androgen Depriv... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer | NCT01214291 | Risk of Bone Fr... | Toremifene | 50 Years - 80 Years | GTx | |
| Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients | NCT05202340 | Prostate Cancer | No intervention | 18 Years - | Chinese University of Hong Kong | |
| Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer | NCT00181584 | Bone Loss Prostate Cancer | Zoledronic acid Placebo | 18 Years - | Massachusetts General Hospital | |
| Living Well on Androgen Deprivation Therapy | NCT02108613 | Prostate Cancer | Exercise Sessio... Nutrition Educa... Peer Support Vo... | - 80 Years | British Columbia Cancer Agency | |
| The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT | NCT06163924 | Cardiovascular ... Prostate Cancer | 18 Years - 80 Years | Chinese University of Hong Kong | ||
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | NCT00148772 | Prostate Cancer | Erlotinib (Tarc... | 18 Years - | NorthShore University HealthSystem | |
| Testosterone Therapy in Castration Resistant Prostate Cancer | NCT03734653 | Prostate Cancer Castration-Resi... | Transdermal Tes... Standard of Car... | 18 Years - 100 Years | University of Colorado, Denver | |
| Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
| Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | NCT03056638 | Prostate Cancer | Degarelix stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases | NCT03569241 | Prostate Cancer Prostate Cancer... Metastatic Canc... Oligometastatic... | whole pelvic ra... metastasis-dire... salvage Lymph N... androgen depriv... | 18 Years - | University Hospital, Ghent | |
| PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases | NCT03569241 | Prostate Cancer Prostate Cancer... Metastatic Canc... Oligometastatic... | whole pelvic ra... metastasis-dire... salvage Lymph N... androgen depriv... | 18 Years - | University Hospital, Ghent | |
| Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study) | NCT03703778 | Prostate Cancer | Androgen depriv... Androgen depriv... Androgen depriv... | 18 Years - | Chinese University of Hong Kong | |
| Staying Strong and Healthy During Androgen Deprivation Therapy (ADT) for Men | NCT02969577 | Prostate Cancer | Exercise Progra... Diet and Nutrit... Usual Care with... | 21 Years - | University of Kansas Medical Center | |
| Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer | NCT00769795 | Prostate Cancer | IMC-A12 Bicalutamide Goserelin | 18 Years - | University of Washington | |
| National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients | NCT04086290 | Prostate Cancer... | RARP SBRT ADT | 18 Years - | Herlev Hospital | |
| Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss | NCT00925600 | Cancer Cataract Low Bone Minera... Osteopenia Osteoporosis Prostate Cancer | Denosumab Placebo | 30 Years - 120 Years | Amgen | |
| Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer | NCT04298983 | Prostate Cancer | Abemaciclib 150... Androgen depriv... Radiation Thera... | 18 Years - | University of Alabama at Birmingham | |
| Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients | NCT02303327 | Prostate Cancer | EBRT + HDR brac... Hypofractionate... Androgen depriv... | 18 Years - | Sir Mortimer B. Davis - Jewish General Hospital | |
| Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix | NCT03202381 | Prostate Cancer | Degarelix | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | NCT03543189 | Prostate Cancer Prostate Diseas... | Nivolumab Brachytherapy External Beam R... Androgen Depriv... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Living Well on Androgen Deprivation Therapy | NCT02108613 | Prostate Cancer | Exercise Sessio... Nutrition Educa... Peer Support Vo... | - 80 Years | British Columbia Cancer Agency | |
| Mild Cognitive Impairment in Men Following Androgen Deprivation | NCT01691976 | Prostate Cancer | Oestrogen Patch... LHRHa | 50 Years - 90 Years | Imperial College London | |
| Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial | NCT05223582 | High-risk Prost... Neoadjuvant The... | Abiraterone ace... Fluzoparib Prednisone Androgen depriv... Radical Prostat... | 18 Years - | Fudan University | |
| ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) | NCT04916613 | Prostate Cancer... | Darolutamide 30... Placebo Androgen depriv... | 18 Years - | UNICANCER | |
| De-implementation of Low Value Castration for Men With Prostate Cancer | NCT03579680 | Cancer of Prost... | ADT ORDER CHECK... PROVIDER SCRIPT... | - | University of Michigan | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | NCT05188911 | Prostate Cancer Castration-resi... Metastatic Dise... | Abiraterone Prednisone Androgen depriv... | 18 Years - 85 Years | Fudan University | |
| Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy | NCT00470834 | Neoplasms, Pros... | dutasteride placebo bicalutamide | 40 Years - 90 Years | GlaxoSmithKline | |
| Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy | NCT00129142 | Prostate Cancer Osteoporosis Fractures | Toremifene Citr... | 50 Years - | GTx | |
| Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | NCT00148772 | Prostate Cancer | Erlotinib (Tarc... | 18 Years - | NorthShore University HealthSystem |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
